64th ASH Annual Meeting and Exposition: 902. Health Services and Quality

Symposia: Health Services and Quality—Lymphoid Malignancies Oral and Poster Abstracts
Poster

Hall D (Ernest N. Morial Convention Center)

Effective Antimicrobial Stewardship in Febrile Neutropenia: A Risk Stratification Tool Combining MASCC Score and Procalcitonin Measurements Reduces Antibiotic Duration and Length of Inpatient Stay for Haemato-Oncology Patients

Keir Pickard, MD¹^*, Joanna Fawcett, MD²^*, Michelle Lannon, MD²^*, Thomas Creasey³^*, Julie Samuel, MD²^*, Alexander Langridge, MD⁴^*, Nicola Redding, MD²^*, Meghan Acres, MD²^* and Gail Jones, MD⁵^*

¹Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, ENG, United Kingdom
²Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
³Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
⁴Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
⁵The Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom

4845

Rituximab Infusion in 30 Minutes' Is Safe and Improves the Flow of Outpatients with Lymphoma Treatment (SPEEDR)

Björn E Wahlin, MD, PhD^1,2, Therese Rådman³^*, Maria Ljungqvist, MD, PhD^4,5^* and Kristina Sonnevi^4,6^*

¹Karolinska Institutet, Department of Medicine, Huddinge, Stockholm, Sweden
²Dept of Hematology, Karolinska University Hospital, Solna, Sweden
³Center of Hematology, Karolinska Universtity Hospital, Stockholm, Sweden
⁴Center of Hematology, Karolinska University Hospital, Stockholm, Sweden
⁵Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden
⁶Karolinska Institutet, Stockholm, Sweden

4846

10-Year Impact on Productivity Costs Associated with Mortality in Stage III or IV Classical Hodgkin Lymphoma Based on the Overall Survival Update of the ECHELON-1 Trial: Application of an Oncology Simulation Model in the United States

Tycel J. Phillips, MD^1,2, Nicholas Liu, PharmD³^*, Brian Bloudek, MS⁴^*, Kristen Migliaccio-Walle⁴^*, Jade Reynolds, BS⁴^* and John M. Burke, MD⁵

¹Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI
²University of Michigan Medical School, Ann Arbor, MI
³Seagen Inc., Bothell, WA
⁴Curta Inc., Seattle, WA
⁵US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO

4847

End-of-Life Therapeutic Burden: A Comparative Study of Hematologic and Solid Tumor Malignancies

Rachel Burstein, MD¹^*, Adir Shaulov²^*, Dina Ben Yehuda, MD²^*, Boaz Nachmias, MD, PhD³^*, Moshe E Gatt⁴ and Ariel Aviv, MD^5,6^*

¹hadassah hospital, Ramat Hasharon, AL, Israel
²Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University, Jerusalem, Israel
³Department of Hematology, Hadassah-Hebrew University Medical Center, Toronto, ON, Canada
⁴Hadassah University Hospital, Jerusalem, Israel
⁵Hematology Unit, HaEmek Medical Center, Afula, Israel
⁶Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel

4848

Cost-Effectiveness Analysis of Motixafortide Versus Plerixafor in Stem Cell Mobilization for Autologous Transplantation in Patients with Multiple Myeloma

Mark Lamotte, MD¹^*, John F. DiPersio, MD, PhD², David Samuel Siegel, MD, PhD³, Haddas Meron, BSc, MBA⁴^* and Laetitia Gerlier, MSc.¹^*

¹Global HEOR, IQVIA, Zaventem, Belgium
²Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
³John Theurer Cancer Center, Division of Multiple Myeloma, Hackensack University Medical Center, Hackensack, NJ
⁴BioLineRx, Modiin, Israel

4849

Sperm Banking in Post-Pubertal Males with Newly Diagnosed High-Risk ALL

Jessica L. Feuerstein, DO¹^* and Burton Appel, MD, MBA²

¹Hackensack University Medical Center, Hackensack, NJ
²Hackensack Univ. Med. Ctr., Hackensack, NJ

4850

Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US)

Mayur Narkhede, MBBS¹, Nicholas Liu, PharmD²^*, Andy Surinach, MPH³^*, Michelle A. Fanale, MD², Kristina S. Yu, PhD, MPH, RPh²^* and Allison Winter, MD⁴

¹University of Alabama-Birmingham, Birmingham, AL
²Seagen Inc., Bothell, WA
³Genesis Research, Hoboken, NJ
⁴Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4851

Disease-Specific Analysis of Drug Approval Delay in Hematologic Malignancies between Japan and the U.S. and between Europe and the U.S

Kensuke Matsuda, MD, PhD^1,2, Sumimasa Nagai, MD, PhD³ and Koichi Sugimoto, MD, Ph.D,²^*

¹Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Bunkyo-Ku, TKY, Japan
²Department of Hematology and Oncology, JR Tokyo General Hospital, Tokyo, Japan
³Department of Medical Development, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan

4852

Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments

Arliene Ravelo, MPH¹^*, Kelley Myers, PhD²^*, Robyn Brumble, MSN, RN³^*, Cooper Bussberg²^*, Brian Koffman, MDCM, DCFP, DABFM, MSEd³^*, Beenish S. Manzoor, PhD, MPH⁴^*, Juliana Biondo, MD¹ and Carol Mansfield, PhD²^*

¹Genentech, Inc., South San Francisco, CA
²RTI Health Solutions, Research Triangle Park, NC
³CLL Society, Chula Vista, CA
⁴AbbVie, Inc., North Chicago, IL

4853

Assessing the Safety of Discharging Patients Receiving High-Dose Methotrexate with Levels Greater Than 0.1 Umol/L

Elaine Xiang, PharmD¹^*, Jamie Chin, PharmD²^*, Jonathan Weltz, DO³^*, Aaron Sango, PharmD¹^*, Meredith Akerman, MS⁴^*, Michael L. Grossbard, MD⁵ and Shella Saint Fleur-Lominy, MD, PhD⁶

¹NYU Langone Health, New York, NY
²Pharmacy, NYU Winthrop Hospital, Mineola, NY
³Division of Oncology-Hematology, NYU Long Island School of Medicine, Mineola, NY
⁴Department of Biostatistics, NYU Winthrop Hospital, Mineola, NY
⁵Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY
⁶Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY

4854

Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Yu-Hua Fu¹^*, Shang-Ju Wu, MD, PhD²^*, Elise Chia-Hui Tan, PhD³^*, Chi-Chuan Wang, PhD^1,4,5^*, Kibum Kim, PhD⁶^*, Wen-Chien Chou, MD, PhD^2,7 and Fang-Ju Lin, PhD^1,4,5^*

¹Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
²Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
³Department of Health Services Administration, China Medical University, Taichung, Taiwan
⁴Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan
⁵School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
⁶Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL
⁷Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

4855

Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study

Michael Wallington¹^*, Xavier Guillaume, MSc, MBA²^*, Emily Mulvihill, MBA³^*, Graceanne R Wayser⁴^*, Vandana Kaul, PhD⁵^*, Claire Graziani-Taugeron, PhD²^*, Mina Shahkarami⁶^* and Kellie J. Ryan, MPH⁷^*

¹AstraZeneca, London, United Kingdom
²Cerner Enviza, Paris, France
³Cerner Enviza, Saint Louis, MO
⁴Cerner Enviza, New York, NY
⁵Cerner Enviza, Jersey City, NJ
⁶AstraZeneca, South San Francisco, CA
⁷Global Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, MD

4856

Successful Outpatient Treatment and Monitoring Following Administration of Various Anti-CD19 Chimeric Antigen Receptor Therapies in B-Cell Lymphomas

Shelby Kirby, BSN¹^*, Daanish Hoda, MD² and Bradley Hunter, MD, MPH¹

¹BMT / Cellular Therapy, LDS Hospital, Intermountain Healthcare, Salt Lake City, UT
²BMT / Cellular Therapy, LDS Hospital, Intermountain Healthcare, SALT LAKE CITY, UT

4857

Real-World Treatment Patterns, Healthcare Resource Utilization, Costs, and Survival Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL)

Mahek Garg, PhD¹^*, Scott F. Huntington, MD, MPH², Justin Puckett, BA³^*, Sachin Kamal-Bahl, PhD⁴^*, Monika Raut, MS, PhD¹^*, Katherine Elizabeth Ryland, PhD⁵ and Jalpa Doshi, PhD⁶^*

¹Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, NJ
²Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
³COVIA Health Solutions, Philadelphia, PA
⁴COVIA Health Solutions, Lansdale, PA
⁵Merck & Co., Inc., Kenilworth, NJ
⁶Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

4858

Early Onset of Smoldering Disease Correlates with Rapid Progression to Symptomatic Multiple Myeloma

Fahrettin Covut, MD¹, Rishil Chopra²^*, Sathya Sri Areti³^*, James J. Driscoll, MD, PhD⁴ and Ehsan Malek, MD⁵

¹Department of Internal Medicine, Case Western Reserve University, Cleveland, OH
²University Hospitals St. John Medical Center, Cleveland
³University Hospitals Cleveland Medical Center, Cleveland, OH
⁴Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
⁵Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Shaker Hts, OH

4859

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Mengyang Di, MD, PhD^1,2, Jessica B Long, MPH¹^*, Iris Isufi, MD³, Francine M. Foss, MD³, Stuart Seropian, MD³, Cary P Gross, MD^1,4^* and Scott F. Huntington, MD, MPH^1,3

¹Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University School of Medicine, New Haven, CT
²Department of Internal Medicine, Hematology/Oncology, Yale University School of Medicine, New Haven, CT
³Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
⁴Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

4860

Use of Clinical Decision Support to Improve the Laboratory Evaluation of Monoclonal Gammopathies

Daniel S. Pearson, MD, PhD¹^*, Dustin McEvoy, BS²^*, Mandakolathur Murali, MD³^* and Anand Dighe, MD, PhD¹^*

¹Department of Pathology, Massachusetts General Hospital, Boston, MA
²Mass General Brigham, Somerville, MA
³Department of Medicine, Department of Pathology, Massachusetts General Hospital, Boston

4861

Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients with Relapsed or Refractory Follicular Lymphoma in the United States

Olalekan O. Oluwole, MBBS¹, Markqayne D. Ray, PharmD, MBA²^*, Katherine L. Rosettie, MPH³^*, Graeme Ball, MA²^*, Jorge Jacob, MS⁴^*, Pinar Bilir, MS³^*, Anik R. Patel, PhD²^* and Caron A. Jacobson, MD⁵

¹Vanderbilt University Medical Center, Nashville, TN
²Kite, A Gilead Company, Santa Monica, CA
³IQVIA, Falls Church, VA
⁴IQVIA, London, United Kingdom
⁵Dana-Farber Cancer Institute, Boston, MA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

902. Health Services and Quality—Lymphoid Malignancies: Poster III